Targeting Tregs in Malignant Brain Cancer: Overcoming IDO.
about
Towards tumor immunodiagnosticsCD8 T Cell-Independent Antitumor Response and Its Potential for Treatment of Malignant GliomasImmunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS SitesSui generis: gene therapy and delivery systems for the treatment of glioblastomaEphs and Ephrins in malignant gliomasTargeting Antitumor Immune Response for Enhancing the Efficacy of Photodynamic Therapy of Cancer: Recent Advances and Future PerspectivesModulatory role of regulatory T cells in a murine model of severe equine asthma.Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and LomustineRegulatory T cells are not a strong predictor of survival for patients with glioblastoma.PEG-rIL-10 treatment decreases FoxP3(+) Tregs despite upregulation of intratumoral IDOA Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed GlioblastomaCD200R/Foxp3-mediated signalling regulates microglial activation.Heme oxygenase-1 protects regulatory T cells from hypoxia-induced cellular stress in an experimental mouse brain tumor model.1-Methyl-tryptophan attenuates regulatory T cells differentiation due to the inhibition of estrogen-IDO1-MRC2 axis in endometriosisMyeloid-derived suppressor cells in gliomas.CNS macrophages and peripheral myeloid cells in brain tumours.Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No?Regulatory T cell subsets in patients with medulloblastoma at diagnosis and during standard irradiation and chemotherapy (PBTC N-11).Immune microenvironment of gliomas.Developing immunotherapeutic strategies to target brain tumors.Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response.p62/SQSTM1 is involved in caspase-8 associated cell death induced by proteasome inhibitor MG132 in U87MG cells.Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseases.HO-1 Induction in Cancer Progression: A Matter of Cell Adaptation.Aspects of Tryptophan and Nicotinamide Adenine Dinucleotide in Immunity: A New Twist in an Old TaleWorkshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer.Thymus-Derived, Peripherally Derived, and in vitro-Induced T Regulatory Cells.IDO1 involvement in mTOR pathway: a molecular mechanism of resistance to mTOR targeting in medulloblastoma.Immune microenvironment of experimental rat C6 gliomas resembles human glioblastomas.Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma.Novel Therapy for Glioblastoma Multiforme by Restoring LRRC4 in Tumor Cells: LRRC4 Inhibits Tumor-Infitrating Regulatory T Cells by Cytokine and Programmed Cell Death 1-Containing Exosomes.IDO1 in cancer: a Gemini of immune checkpoints.Immunotherapies for malignant glioma.Anti-GITR therapy promotes immunity against malignant glioma in a murine model.Small-Molecule Targets in Tumor Immunotherapy
P2860
Q26738691-4F469EF6-9A06-4A5C-9A6A-809485BC9E1EQ26740520-DF820C0D-5099-44AC-B1A0-AAA5BD15453BQ26798402-8E662226-6FA4-45AE-A0A2-301E3478D73EQ26850467-D0EBCE38-9F29-42B1-B7C9-78F68D4785E0Q27015780-A0043B60-5B8D-46A3-9E48-894EE1E8D292Q28066286-5A7EB76C-C4EA-46A6-89F7-D18A22D7BE80Q33617780-F113476B-39B6-4BD5-B81B-E9397A16308DQ33755077-3C30450E-FE7D-47BF-B0DC-98267288B6F6Q35789008-5B202CA0-955E-4370-A274-2591C92BA2C8Q37222162-37484F9E-9AF6-41BF-BE0A-CB21B8875127Q37262109-7D281899-5B79-4B03-9D25-9E54B1BF84D5Q37330271-AD167AD6-5B7F-4B23-882C-4150B12D09B3Q37598477-9E29095C-D5BC-48DF-A112-4902006E5ED7Q37603455-59E63513-C2B4-4D2E-8597-C7DF2F2EC076Q37727645-C5B72FA1-F0A1-424E-BA2D-C4292529FC5DQ38203815-1541D678-BFC3-4017-8521-2DA6EE389046Q38348844-489F292F-16FE-4656-BC38-23F1BA2AC1DCQ38616499-383C5450-8A4B-4EF1-8618-C0213608A4FAQ38712457-86E6D57C-D23A-4E18-A0E0-AC5AD4F50665Q38851464-2C081753-9DB6-4AD9-8D72-EA0F5AE305B7Q38912265-A19D9774-C44A-411A-B03B-B0EE25C24C27Q38997499-BD1EB67B-E1EF-44E6-AF43-3A628B013DF9Q39185463-6FBCE7E3-6625-4015-91F3-7BA9DB7E5229Q39285687-ADBFA51E-35DA-4228-BF8E-869E06DFD42BQ39403381-6B9D2492-1364-4D57-ACE0-0DA2AA04B252Q41706958-B562207C-0690-4E3E-A5BA-C7574F909B6FQ41889070-3FA5D0A4-AA1F-410F-BF58-D0AEFF911957Q42324668-9712B8B1-56F4-4B4B-8B68-8C239AEF4A2FQ47135965-A828D5BA-656D-4C79-A15F-134F20AE1142Q47141309-C896B2A8-9AE7-483B-B830-3164DA951DE9Q47221313-30E3251A-72BB-406C-9AE4-71F3502A9942Q47836812-03F6AA62-FDD0-4E5D-BC5F-91CE32ADE88EQ47915209-D3B4732A-F20C-4A7E-811B-F9A6CA33AD82Q48480477-0E50B55E-6295-49D5-9707-31B884ED2556Q56890719-71A4A8E1-CAD0-4D2A-BBE3-4631D94C0BE3
P2860
Targeting Tregs in Malignant Brain Cancer: Overcoming IDO.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Targeting Tregs in Malignant Brain Cancer: Overcoming IDO.
@en
type
label
Targeting Tregs in Malignant Brain Cancer: Overcoming IDO.
@en
prefLabel
Targeting Tregs in Malignant Brain Cancer: Overcoming IDO.
@en
P2093
P2860
P356
P1476
Targeting Tregs in Malignant Brain Cancer: Overcoming IDO
@en
P2093
Alan Chang
Maciej S Lesniak
P2860
P356
10.3389/FIMMU.2013.00116
P577
2013-05-15T00:00:00Z